Introduction
============

Estrogens play a pivotal role in the development and proliferation of hormone-dependent breast cancer, which represents the most common type of cancer in women ([@B12]). Estrogens act via nuclear ERs ([@B24]) and the selective ER modulator tamoxifen has been used successfully for antiestrogen breast cancer therapy for four decades ([@B43]). Despite a significant decline of free estrogens after menopause, a high percentage of all hormone-dependent breast cancer cases develop in this phase of life ([@B25]). In contrast to free estrogens (E~1~ and E~2~), the sulfo-conjugated steroid forms, in particular estrone-3-sulfate (E~1~S) and DHEAS, persist at higher plasma concentrations even after menopause ([@B49]; [@B17]). These sulfo-conjugated steroids can be re-converted into active free estrogens in breast cancer tissue via cleavage of the sulfate group by the STS and further conversion by the enzymes 3β-hydroxysteroid dehydrogenase and aromatase in the case of DHEA ([@B52]; [@B45]; [@B27]; [@B58]; [@B53]). Inhibitors of STS (STX64) and aromatase (anastrozole, letrozole) can block this intracrine formation of estrogens and, therefore, are used for clinical (aromatase inhibitors) or experimental (STS inhibitors) breast cancer therapy ([@B51]; [@B56]).

Prior to intracellular conversion of E~1~S and DHEAS, these negatively charged hydrophilic molecules first have to enter breast cancer cells via carrier-mediated uptake. Several uptake transporters for sulfo-conjugated steroid hormones have been characterized so far, including members of the OATP and the OAT families ([@B50]; [@B38]). Most of these OATP/OAT carriers are multi-specific and are involved in the transport of drugs, drug conjugates, bile salts, and some other charged molecules ([@B10]; [@B23]). Some of them are even expressed in breast cancer tissue or breast cancer cell lines, including OATP1A2, OATP1B3, OATP2B1, OATP3A1, OATP4A1, and others, thus making them candidates for steroid sulfate uptake in breast cancer ([@B48]; [@B42]; [@B39]).

In the present study, we analyzed expression of the SOAT (gene name *SLC10A6*) in breast cancer. This carrier transports all physiologically occurring sulfo-conjugated steroid hormones, including E~1~S (K~m~ of 12 μM), DHEAS (K~m~ of 29 μM) and many others ([@B18]; [@B15]; [@B21]). In contrast, free steroids, steroid glucuronides, or bile salts are not transported by SOAT. Therefore, this carrier can be regarded as highly specialized for sulfo-conjugated steroid hormones ([@B18]; [@B21]), distinguishing it from OATPs and OATs. Another difference to the OATP/OAT carriers is the fact that SOAT mediates a secondary active transport of its substrates. SOAT is highly expressed in germ cells of the testis of men and mice ([@B15]; [@B22]). Here, the SOAT-mediated import of sulfo-conjugated steroid hormones was suggested to participate in the overall regulation of spermatogenesis and fertility ([@B15]; [@B22]; [@B3]). In addition, relatively high SOAT expression was detected in pancreas, placenta, and mammary gland ([@B18]).

In the present study, high SOAT mRNA expression was found in a large set of breast cancer specimen. The SOAT protein was localized in the normal ductal epithelium of the breast and strong SOAT expression was found in breast biopsies with different pathologies. Hormone-dependent breast cancer T47D cells, stably transfected with SOAT, showed significant proliferation after incubation with E~1~S at physiologically relevant concentrations. This proliferation could be blocked successfully by SOAT inhibition, demonstrating that SOAT could be regarded as an interesting new drug target from the group of E~1~S uptake carriers for antiproliferative breast cancer therapy.

Materials and Methods {#s1}
=====================

Materials and Chemicals
-----------------------

All of the chemicals, unless otherwise stated, were from Sigma-Aldrich (Taufkirchen, Germany). The compound 4-SMP was kindly provided by Prof. Dr. Hansruedi Glatt (Potsdam-Rehbrücke). \[^3^H\]estrone-3-sulfate (\[^3^H\]E~1~S, 57 Ci/mmol) was purchased from PerkinElmer (Boston, MA, United States) and \[methyl-^3^H\]thymidine (79 Ci/mmol) was obtained from GE Healthcare (Amersham, United Kingdom). TissueScan^TM^ breast cancer cDNA arrays I-IV (BCRT101-BCRT104) were obtained from OriGene (Rockville, MD, United States).

Breast Cancer cDNA Arrays
-------------------------

In order to analyze SOAT expression in breast cancer, the following TissueScan^TM^ cDNA arrays were commercially obtained from OriGene (Rockville, MD, United States): Breast Cancer cDNA Array I (BCRT101), Breast Cancer cDNA Array II (BCRT102), Breast Cancer cDNA Array III (BCRT103), and Breast Cancer cDNA Array IV (BCRT104). Each array contains 48 samples covering tumors of different histopathology, stages and grades. For each tumor cDNA, detailed information is available online^[1](#fn01){ref-type="fn"}^, including age, gender and ethnicity of the patient, as well as diagnosis, pathology report, histologic type, tissue images, tumor grade (based on the Nottingham grading system, [@B13]) and tumor stage (according to the [@B2]). In addition, the receptor status is provided for the ER, PR, and HER2.

Stable Transfection of T47D Cells With the SOAT Construct
---------------------------------------------------------

The human breast cancer cell line T47D (obtained from Dr. Bernhard Ugele, Department of Gynecology and Obstetrics, University Hospital Munich, Germany) was maintained in a 1:1 mixture of DMEM and Ham's F12 nutrient mixture (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS, [L]{.smallcaps}-glutamine (4 mM), penicillin (100 units/ml), and streptomycin (100 g/ml) at 37°C, 5% CO~2~, and 95% humidity. For stable transfection of T47D cells, the full length SOAT coding sequence ([@B18]) was subcloned into the pcDNA3.1 vector (Invitrogen) using *Hin*dIII and *Xba*I restriction sites. The SOAT-pcDNA3 vector was verified by DNA sequencing and used for stable transfection of T47D cells by electroporation. Briefly, subconfluent T47D cells were trypsinized and resuspended in PBS containing 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH~2~PO~4~, and 7.3 mM Na~2~HPO~4~ at pH 7.4. Approximately 10^6^ cells were transferred to a 4 mm Gene Pulser Cuvette (Bio-Rad Laboratories, Munich, Germany), mixed with 20 μg plasmid and incubated for 10 min on ice. The electroporation was performed on the Gene Pulser Xcell System (Bio-Rad Laboratories) using a single electrical pulse with initial field strength of 120 V, discharged from the 960 μF capacitor and time constant of 10 ms. After an additional 10 min of incubation on ice, cells were plated onto 10 cm culture dishes. After 24 h, selection medium was added containing 750 μg/ml G418 sulfate and cells were further incubated, changing the medium every 3 days. After 12 days, several cell clones were pooled from the culture dishes (T47D-SOAT) and SOAT expression was analyzed by real-time PCR analysis. For control, T47D cells were also transfected with an empty pcDNA3.1 vector. These T47D-control cells were processed in the same manner as the T47D-SOAT cells.

Expression Analysis by Real-Time PCR
------------------------------------

TissueScan^TM^ breast cancer cDNA arrays were directly used for expression analysis of SOAT by real-time PCR. Symplekin (SYMPK, Uniprot Q92797) that showed particularly low expression variability in breast cancer tissue and cell lines ([@B59]) was used as endogenous control. RNA was isolated from T47D-SOAT and T47D-control cells grown in 10 cm petri dishes under DMEM/F12 medium. Cells were seeded at 10^6^ cells per well for each cell type and RNA was isolated following 72 h of growth. The medium and any detached cells were removed from the wells. Total RNA isolation was performed by using the peqGOLD RNAPure reagent (PeqLab, Erlangen, Germany) according to the manufacturer's instructions. The isolated RNA was dissolved in diethylpyrocarbonate-treated water and stored at -80°C until use. The RNA concentration was determined by measuring absorbance at 260 nm with a Beckmann spectrophotometer DU-640 (Beckmann, Munich, Germany). Complementary cDNA was synthesized from the RNA samples using the Advantage RT-for-PCR kit (BD Clontech, Heidelberg, Germany) according to the manufacturer's instructions. For real-time PCR expression analysis of T47D cells, beta-actin was used as endogenous control. Relative gene expression analysis was performed by real-time PCR amplification on an ABI PRISM 7300 thermal cycler (Applied Biosystems, Darmstadt, Germany) using the TaqMan Gene Expression Assays (Applied Biosystems, Darmstadt, Germany) Hs01399354_m1 for SOAT, Hs00165853_m1 for STS, Hs00174860_m1 for ERα, Hs99999903_m1 for beta-actin, and Hs00191361_m1 for SYMPK. Real-time amplification was performed in 96-well optical plates using 5 μl cDNA, 1.25 μl TaqMan Gene Expression Assay, 12.5 μl TaqMan Universal PCR Master Mix and 6.25 μl water in each 25 μl reaction. The plates were heated for 10 min at 95°C, and 45 cycles of 15 s at 95°C and 60 s at 60°C were applied. Relative expression (ΔC~T~) was calculated by subtracting the signal threshold cycle (C~T~) of the endogenous control from the C~T~ value of the respective target.

Transport Assays in T47D Cells
------------------------------

For transport studies, 12-well plates were coated with poly-[L]{.smallcaps}-lysine for better attachment of the cells. Twenty thousand cells/well were plated and grown under DMEM/F12 medium for 3 days. Before starting the transport experiments, T47D cells were washed three times with PBS and incubated with sodium transport buffer containing 142.9 mM NaCl, 4.7 mM KCl, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 1.8 mM CaCl~2~, and 20 mM HEPES (pH 7.4). When transport assays were performed in sodium-free transport buffer, sodium chloride was substituted with equimolar concentrations of choline chloride. T47D-SOAT and T47D-control cells were incubated with 250 μl of transport buffer containing radiolabeled \[^3^H\]estrone-3-sulfate (\[^3^H\]E~1~S) at 37°C for 30 min. Transport assays were terminated by removing the transport buffer and washing five times with ice-cold PBS. Cell monolayers were lysed in 1 N NaOH with 0.1% SDS, and the cell-associated radioactivity was determined in a Wallac 1409 liquid scintillation counter (Pharmacia, Freiburg, Germany). The protein content was determined according to [@B29] using aliquots of the lysed cells with bovine serum albumin as a standard. LC-MS/MS was used to measure E~1~S concentrations in the cell culture medium at the end of the uptake phase as described before ([@B16]).

Cell Proliferation Assays in T47D Cells
---------------------------------------

T47D cells were grown for at least 1 week in DMEM/F12 supplemented with 10% FCS. Then, for proliferation assays, the cells were starved for 4 days in steroid-free phenol red-free DMEM/F12 medium supplemented with 5% dextran-coated charcoal-treated FCS (DCC-FCS). DCC-FCS was prepared by incubating 0.5 g DCC in 100 ml FCS over 24 h at 4°C, followed by filtration (pleated filter MN 615 ¼, Macherey-Nagel, Düren, Germany). T47D cells were plated at a density of 10,000 or 20,000 cells/well in 24-well plates. Twenty four hour after seeding, E~2~ (final concentration 10^-9^ M) or E~1~S (final concentrations 10^-12^ to 10^-4^ M) were added from stock solutions containing DMSO, considering that the final DMSO concentration in the medium was below 0.1%, and cells were incubated at 37°C, 5% CO~2~, and 95% humidity. The negative control included solvent alone. Seven days after seeding, cells were treated with \[methyl-^3^H\]thymidine with final concentrations of 1 μCi/ml at 37°C for 2 h as reported ([@B11]). After incubation, the medium was removed and cells were washed five times with ice-cold PBS. Then, cell lysis was performed with 500 μl of 1 N NaOH and the radioactivity of the lysates was determined by liquid scintillation counting.

Detection of SOAT in Breast Tissues by Immunohistochemistry
-----------------------------------------------------------

Immunohistochemistry was performed on breast biopsies of different pathologies, i.e., intraductal papilloma, atypical ductal hyperplasia, intraductal carcinoma, and invasive ductal carcinoma. Paraffin-embedded tissue slides were prepared at the Department of Pathology at Atatürk University. Use of human tissue was approved by the ethics committee of Atatürk University, School of Medicine, No: 4/22, 02.06.2015. Tissue sections were incubated with the primary antibody SLC10A6 (C-13) (sc-136875, Santa Cruz, Dallas, TX, United States) at 1:100 dilution, followed by incubation with biotinylated goat anti-rabbit E0432 secondary antibody (Dako, Glostrup, Denmark) at 1:200 dilution in tris-buffered saline. Afterward, sections were incubated with the avidin-biotin complex (ABC Vectastain, Vector, Burlingame, CA, United States) and developed with 3-amino-9-ethylcarbazole (AEC, Biologo, Kronshagen, Germany). Counterstaining was performed with hematoxylin and slides were mounted with Kaiser's glycerol gelatin (Merck, Darmstadt, Germany). Validation of the SLC10A6 C-13 antibody and the IHC protocol has been previously performed for human placenta ([@B55]).

Statistical Methods
-------------------

Unless otherwise indicated, values are represented as means ± SD. All graphs and calculations were prepared using the GraphPad Prism software 6.07 (GraphPad Software, La Jolla, CA, United States). Student's unpaired *t-*test and one-way ANOVA with Tukey's multiple comparisons test was performed to determine statistical significance. Differences were considered significant at *p \<* 0.05. The EC~50~ values were calculated by non-linear regression analysis from sigmoidal dose-response curves.

Results
=======

SOAT mRNA Expression in Breast Cancer Specimen
----------------------------------------------

In order to analyze SOAT expression in different types of breast cancer, the OriGene TissueScan^TM^ Breast Cancer cDNA Arrays I-IV were screened for SOAT expression by real-time PCR. The arrays included 192 cDNAs from breast cancer samples of different pathology, stages, grades, and receptor status. All samples with pathology verification were included in the data analysis shown in **Figure [1](#F1){ref-type="fig"}**. Samples without pathology (array classification: within normal limits) were excluded from the analysis. SOAT mRNA expression was normalized by SYMPK expression, which has previously demonstrated particularly low variability of expression in breast cancer tissue and cell lines ([@B59]). SOAT expression was undetectable only in very few samples and showed large variability in the tumor samples ranging from ΔC~T~ of 0.83 (very high expression) up to ΔC~T~ of 10 (very low expression). Nearly all tumor samples were classified as breast adenocarcinoma, with the vast majority being ductal. Only three cDNAs derived from ductal carcinoma *in situ* and one sample was from a squamous cell carcinoma of the breast. Interestingly, this squamous cell carcinoma showed extremely high SOAT expression that was even higher than in human testis, representing the organ with the highest physiological SOAT expression in man ([@B18]; [@B15]). In order to determine if SOAT mRNA expression correlates with tumor grade, stage, or receptor status, sub-analyses were performed. As indicated in **Figure [1A](#F1){ref-type="fig"}**, SOAT expression was not significantly different between tumors with grades G1, G2, or G3, or between tumors of different stages (I-IV). Furthermore, there was no difference in SOAT expression in tumors with different ER, PR, or HER2 status. Even in TN breast cancer samples, SOAT expression was not different from the other groups (**Figure [1B](#F1){ref-type="fig"}**). Further sub-analyses were performed in the adenocarcinoma samples including age and ethnos (**Figure [1C](#F1){ref-type="fig"}**). No effect of age on the SOAT mRNA expression of breast adenocarcinomas was detected and SOAT expression was comparable between Caucasians and African Americans.

![SOAT mRNA expression in breast cancer. SOAT mRNA expression was analyzed in the TissueScan^TM^ Breast Cancer cDNA Arrays I-IV, including 176 tumor cDNAs with different classifications (histopathology, grade, stage, and receptor status). Expression of SYMPK was used as endogenous control and ΔC~T~ values are depicted at the *y*-axis. A cut-off was set at C~T~ of 40. Sub-analyses were performed, including **(A)** tumor grade and stage, **(B)** receptor status for ER, PR, HER2 and triple negative breast cancer (TN), and **(C)** age and ethnos. As the cDNA arrays were not equally distributed for the analyzed subgroups, every single value is depicted for better clarity and additional box-whiskers-plots are given. For analysis of statistical significance, one-way ANOVA with Tukey's multiple comparisons test was performed. Differences with *p* \< 0.05 were not detected.](fphar-09-00941-g001){#F1}

SOAT expression was also analyzed in individual breast cancer samples at the protein level with the SLC10A6 (SOAT) C-13 antibody by IHC. Whereas SOAT expression was relatively low in the ductal epithelium of normal breast tissue (**Figure [2A](#F2){ref-type="fig"}**), strong SOAT immunoreactivity was detected in ductal hyperplasia (**Figure [2B](#F2){ref-type="fig"}**), intraductal papilloma (**Figure [2C](#F2){ref-type="fig"}**), atypical ductal hyperplasia (**Figure [2D](#F2){ref-type="fig"}**), intraductal carcinoma (**Figure [2E](#F2){ref-type="fig"}**), and invasive ductal carcinoma (**Figure [2F](#F2){ref-type="fig"}**).

![Expression of the SOAT protein in breast cancer specimen. Expression of the SOAT protein was analyzed in different breast cancer specimen by IHC with the SOAT C-13 antibody (1:100 dilution, AEC staining, hematoxylin counter stain), primary magnification × 40. Insets: Negative control without the primary antibody, primary magnification × 40. **(A)** SOAT expression in the ductal epithelium of normal breast tissue. **(B)** Strong SOAT immunoreactivity of the ductal epithelium in usual ductal hyperplasia. **(C)** Expression of SOAT in intraductal papilloma and expression along the ductal epithelium with strong apical lining. **(D)** Strong SOAT immunoreactivity in atypical ductal hyperplasia. **(E)** Severe immunolabeling with the SOAT antibody in intraductal carcinoma. **(F)** Invasive ductal carcinoma with strong and widespread SOAT expression.](fphar-09-00941-g002){#F2}

Generation of Stably Transfected T47D-SOAT Cells
------------------------------------------------

In order to investigate the role of the carrier-mediated import of E~1~S by SOAT for the proliferation of breast cancer cells, we chose the breast cancer cell line T47D as an *in vitro* model. T47D cells have previously been described as ER expressing and they showed estrogen dependent proliferation after incubation with E~2~ and E~1~S at physiologically relevant concentrations ([@B40]). However, compared to breast cancer tissue (see **Figure [1](#F1){ref-type="fig"}**), where SOAT expression could be readily detected and quantified in nearly all specimen, SOAT expression was very low in T47D-control cells and was at the border of detectability (C~T~∼37.9) in the real-time PCR expression analysis. Therefore, in the present study, T47D cells were stably transfected with the SOAT-pcDNA3 construct in order to increase SOAT expression and mimic the situation *in vivo*. Different cell clones were pooled from the culture dishes (further referred to as T47D-SOAT). As control, T47D cells were transfected with an empty pcDNA3 vector (T47D-control). SOAT expression was analyzed by real-time PCR and revealed significantly higher mRNA expression levels in the T47D-SOAT cells compared with the T47D-control cells (ΔC~T~ = 5.4 ± 0.3 vs. ΔC~T~ = 18.0 ± 0.5). In contrast, mRNA expression levels of STS (ΔC~T~ = 10.4 ± 0.4 vs. ΔC~T~ = 9.7 ± 1.2) and ERα (ΔC~T~ = 5.2 ± 0.3 vs. ΔC~T~ = 5.5 ± 0.7) were not significantly different between T47D-SOAT and T47D-control cells.

Transport Studies in SOAT-Transfected T47D Cells
------------------------------------------------

In order to verify functional SOAT carrier expression in the cell membrane of the T47D-SOAT cells, we performed transport experiments with \[^3^H\]E~1~S as substrate under both sodium and sodium-free conditions. The uptake of 100 nM E~1~S significantly increased over time in the T47D-SOAT cells only in the presence of sodium, demonstrating significant sodium-dependent uptake, which is a clear characteristic of SOAT. T47D-control cell showed slightly higher E~1~S uptake in the presence of sodium compared to sodium-free conditions, but without reaching the level of significance (**Figure [3A](#F3){ref-type="fig"}**). At a physiologically relevant concentration of 10 nM, T47D-SOAT cells also showed significantly higher sodium-dependent uptake of E~1~S compared with T47D-control cells (**Figure [3B](#F3){ref-type="fig"}**). In order to verify that under incubation with 10 nM E~1~S, this compound is indeed taken up into the cells, an additional medium depletion assay was performed and the E~1~S concentration was determined from the medium at the end of incubation by means of LC-MS/MS. As expected, the medium of the T47D-SOAT cells contained significantly lower residue concentrations of E~1~S compared to the medium of the T47D-control cells (**Figure [3C](#F3){ref-type="fig"}**).

![Sodium-dependent uptake of E~1~S into T47D-SOAT cells. **(A)** T47D-SOAT and T47D-control cells were incubated with 100 nM \[^3^H\]E~1~S at 37°C in transport buffer containing Na^+^ or without Na^+^ (sodium-free control). Cell-associated radioactivity was analyzed at the indicated time points. **(B)** Transport of \[^3^H\]E~1~S at 10 nM over 30 min. Data in **(A,B)** represent means ± SD of triplicate determinations. ^∗^Significantly higher transport compared with T47D-control cells and the sodium-free controls (one-way ANOVA with Tukey's multiple comparisons test with *p* \< 0.05). **(C)** Determination of E~1~S concentrations by LC-MS/MS in the cell culture medium at the end of the uptake phase. Data represent means ± SD of two independent experiments, each with triplicate determinations. ^\#^Significantly different between T47D-SOAT and T47D-control cells (unpaired *t*-test with *p* \< 0.05).](fphar-09-00941-g003){#F3}

E~1~S-Stimulated Proliferation of T47D-SOAT Cells
-------------------------------------------------

In order to analyze the estrogen-dependent proliferation of the transfected cell lines, T47D-SOAT and T47D-control cells were grown in DCC-FCS medium supplemented with 10^-9^ M E~2~ (positive control), increasing concentrations of E~1~S ranging from 10^-12^ M to 10^-4^ M, or solvent alone (negative control). Both cell lines showed significantly increased proliferation under E~2~ treatment and this proliferation occurred at equal levels for the SOAT-T47D and SOAT-control cells (**Figure [4A](#F4){ref-type="fig"}**). After treatment with E~1~S at increasing concentrations, both cell lines showed increased proliferation, but with different profiles. Beginning at 10^-11^ M E~1~S, T47D-SOAT cells showed significantly enhanced proliferation compared to T47D-control cells with a maximum proliferation at 10^-7^ M. In contrast, T47D-control cells did not start to proliferate until 10^-9^ M E~1~S and required 10^-6^ M E~1~S for maximum proliferation (**Figure [4A](#F4){ref-type="fig"}**). Within the concentration range of 10^-11^ to 10^-8^ M E~1~S, T47D-SOAT showed significantly higher proliferation compared to T47D-control cells. Half-maximal stimulation (ED~50~) of the E~1~S-stimulated proliferation occurred at concentrations of 2.2 nM and 21.7 nM for the T47D-SOAT and T47D-control cells, respectively (**Figure [4B](#F4){ref-type="fig"}**). This indicates that SOAT-mediated transport of E~1~S at physiologically relevant concentrations significantly stimulated the proliferation of T47D cells.

![E~1~S-dependent proliferation of T47D-SOAT cells. SOAT-transfected T47D cells (T47D-SOAT, filled bars in **A**, black squares in **B**) and mock-transfected T47D cells (T47D-control, open bars in **A**, open squares in **B**) were plated at 10,000 cells/well in 24-well plates and were cultured in phenol red-free DMEM/F12 containing 5% DCC-FCS over 7 days. The culturing medium was supplemented with 10^-9^ M E~2~ for positive control or increasing concentrations of E~1~S ranging from 10^-12^ M to 10^-4^ M. For negative control, cells were treated with solvent alone. Seven days after seeding, the cells were incubated with 1 μCi/ml \[^3^H\]thymidine for 2 h at 37°C, 5% CO~2~, and 95% humidity. After five cycles of washing with PBS, cells were subjected to liquid scintillation counting. Data represent the means ± SD of quadruplicate determinations of three independent experiments (*n* = 12). **(A)** ^∗^Significantly higher \[^3^H\]thymidine incorporation compared with negative control (one-way ANOVA with Tukey's multiple comparisons test with *p* \< 0.05). ^\#^Significantly higher \[^3^H\]thymidine incorporation in T47D-SOAT compared with T47D-control cells (*p* \< 0.05, unpaired *t*-test). **(B)** Values were fitted to concentration response curves by non-linear regression analysis. Proliferation was determined relative to the top (100%) and bottom (0%) values that were derived from the sigmoidal dose response calculation. The EC~50~ values were 2.2 ± 0.3 nM and 21.7 ± 2.1 nM for the T47D-SOAT and T47D-control cells, respectively. Data represent means ± SEM.](fphar-09-00941-g004){#F4}

In order to block this increased proliferation via SOAT, 4-SMP was used as an inhibitor. 4-SMP proved to be one of the most potent inhibitors of SOAT in a previous study ([@B18]). Indeed, incubation of T47D-SOAT cells with 25 μM 4-SMP completely blocked cell proliferation by E~1~S (**Figure [5](#F5){ref-type="fig"}**), while 4-SMP alone had no effect on the cell proliferation of T47D-SOAT and T47D-control cells. Furthermore, 4-SMP had no effect on the E~2~-stimulated cell proliferation of T47D-SOAT cells, which occurs independent from SOAT-mediated transport (**Figure [5](#F5){ref-type="fig"}**, right panel).

![Inhibition of the E~1~S-dependent proliferation of T47D-SOAT cells. Stably SOAT-transfected T47D cells (T47D-SOAT) and mock-transfected T47D cells (T47D-control) were plated at 20,000 cells/well in 24-well plates and were cultured in phenol red-free DMEM/F12 containing 5% DCC-FCS. The culturing medium was supplemented with 10^-8^M E~1~S, 10^-9^ M E~2~ or solvent alone (control). Additionally, 25 μM of the SOAT inhibitor 4-SMP were added to the culturing medium as indicated. After 6 days of cultivation, the cells were incubated with 1 μCi/ml \[^3^H\]thymidine for 2 h at 37°C, 5% CO~2~, and 95% humidity. After five cycles of washing with PBS, cells were subjected to liquid scintillation counting. Data represent means ± SD of quadruplicate determinations of a representative experiment. ^∗^Significantly different from solvent control (one-way ANOVA with Tukey's multiple comparisons test with *p* \< 0.05). ^\#^Significantly higher \[^3^H\]thymidine incorporation in T47D-SOAT compared with T47D-control cells (*p* \< 0.05, unpaired *t*-test).](fphar-09-00941-g005){#F5}

In further experiments, the time course of E~1~S-stimulated T47D cell proliferation was analyzed in further detail with and without 4-SMP as inhibitor of SOAT. Both cell lines, T47D-SOAT and T47D-control, significantly increased their proliferation from days 4 to 6 under incubation with 10 nM E~1~S, but at day 6, T47D-SOAT cells showed significantly higher \[^3^H\]thymidine incorporation compared with the T47D-control cells. In cells additionally incubated with 4-SMP, proliferation was blocked and was not different from the control groups without E~1~S incubation (**Figure [6](#F6){ref-type="fig"}**). Again, 4-SMP alone had no effect on cell proliferation.

![Time course of the E~1~S-dependent proliferation of T47D-SOAT cells. T47D-SOAT and T47D-control cells were plated at 20,000 cells/well in 24-well plates and were cultured in phenol red-free DMEM/F12 containing 5% DCC-FCS. The culturing medium was supplemented with 10^-8^ M E~1~S, 25 μM 4-SMP or solvent alone. Additionally, 10^-8^ M E~1~S were incubated together with the SOAT inhibitor 4-SMP at 25 μM. After 2, 3, 4, 5, and 6 days of cultivation, the cells were incubated with 1 μCi/ml \[^3^H\]thymidine for 2 h at 37°C, 5% CO~2~, and 95% humidity. After five cycles of washing with PBS, cells were subjected to liquid scintillation counting. Data represent the means ± SD of quadruplicate determinations of a representative experiment. ^∗^Significant increase compared to day 2 (*p* \< 0.05, one-way ANOVA with Tukey's multiple comparisons test). ^\#^Significantly higher \[^3^H\]thymidine incorporation in T47D-SOAT compared to T47D-control cells (*p* \< 0.05, unpaired *t*-test).](fphar-09-00941-g006){#F6}

Discussion
==========

As has been known for a long time, breast tumor tissue is able to metabolize steroids from sulfated precursors, which are available even after menopause, to biologically active estrogens ([@B1]; [@B37]). Most studies in this field focus on the metabolic steps involved in estrogen formation, and simply presume intracellular availability of the mostly sulfated precursors ([@B28]). However, sulfo-conjugated steroids are negatively charged molecules and can only enter target cells via carrier-mediated uptake ([@B38]). Therefore, several previous studies have investigated the expression of uptake carriers for sulfated steroids in the normal mammary gland and breast cancer tissue, including OATP1A2, OATP2B1, OATP3A1, OATP4A1, and OATP1B3 ([@B47]; [@B36]; [@B35]; [@B60]; [@B26]; [@B7]). Furthermore, E~1~S uptake carrier expression was demonstrated in different hormone-dependent breast cancer cell lines, such as OATP1A2, OATP3A1, and OATP4A1 in T47D cells ([@B40], [@B41]; [@B35]) as well as OATP1A2, OATP2B1, OATP3A1, and OATP4A1 in MCF7 cells ([@B41]; [@B35]; [@B60]; [@B31]; [@B57]; [@B5], [@B6], [@B8]; [@B34]). Overall these studies demonstrated that carrier-mediated import of E~1~S in breast cancer cells can stimulate their proliferation and thus these carriers were suggested as potential drug targets ([@B42]; [@B39]).

In the present study, we only focused on the expression of SOAT in breast cancer and aimed to analyze its role for hormone-dependent proliferation. SOAT was first cloned from rat adrenal gland and demonstrated significant transport of E~1~S and DHEAS ([@B19]). Later, the human SOAT transcript was cloned ([@B18]). The substrate spectrum of SOAT was intensively analyzed and revealed specific transport of all physiologically occurring sulfo-conjugated steroid hormones, being E~1~S, 17β-estradiol-3-sulfate, 17β-estradiol-17-sulfate, pregnenolone sulfate, 17α-OH-pregnenolone sulfate, androsterone sulfate, epiandrosterone sulfate, testosterone sulfate, epitestosterone sulfate, 5α-dihydrotestosterone sulfate, androstenediol sulfate, DHEAS, and 16α-OH-DHEAS ([@B18]; [@B15]; [@B55]; [@B21]). Sulfo-conjugated bile salts, bromosulfophthalein (BSP, a dye used in liver function tests), and the sulfooxymethylpyrenes 2-SMP and 4-SMP were identified as effective SOAT inhibitors ([@B18]). Apart from high SOAT expression in the testis, placenta, lung and skin, SOAT also showed relatively high mRNA expression in the mammary gland ([@B18]). Here, in the present study the SOAT protein was localized to the ductal epithelium (**Figure [2](#F2){ref-type="fig"}**). Based on this data, it was not surprising that SOAT showed high expression in different pathologies of the breast with a clear ductal staining pattern in IHC, including ductal hyperplasia, intraductal papilloma and intraductal carcinoma (**Figure [2](#F2){ref-type="fig"}**). It can be supposed that, in addition to other E~1~S carriers from the OATP family, SOAT expression in ductal hyperplasia and intraductal carcinoma contributes to the import of E~1~S (and probably also E~2~S) and therefore provides the precursors for the intracrine formation of pro-proliferative E~2~. Based on this mechanism, SOAT can be regarded as an additional drug target for anti-proliferative breast cancer therapy from the group of E~1~S uptake carriers. Against this background, it is interesting to note that SOAT expression was detected in a wide range of breast cancer specimen. Most of them represent adenocarcinoma of the breast with ductal localization (**Figure [1](#F1){ref-type="fig"}**). SOAT expression does not correlate with tumor stage, grade or receptor status. Therefore, SOAT might be an interesting drug target in a wide variety of breast tumors.

In order to verify the role of SOAT for the E~1~S-dependent proliferation of breast cancer cells, we intended to generate an *in vitro* model that mimics the *in vivo* situation as near as possible. Different ER positive breast cancer cell lines such as T47D and MCF7 have emerged as *in vitro* models for proliferation studies in the past ([@B30]; [@B46]; [@B14]; [@B9]; [@B54]; [@B33], [@B32]). Of those, we used T47D cells, as their intracrine estrogen synthesis is well characterized and E~1~S uptake carrier expression has been investigated previously on these cells ([@B47]; [@B40]; [@B36]). However, as demonstrated by real-time PCR, SOAT expression seems to be down-regulated in T47D cells compared to breast cancer tissue. Therefore, we generated a SOAT-transfected T47D-SOAT cell line as well as a mock-transfected T47D-control cell line for proliferation assays. In the T47D-SOAT cells, high SOAT mRNA expression was confirmed by real-time PCR at the transcriptional level as well as by significant sodium-dependent transport of \[^3^H\]E~1~S at the level of the active transporter protein (**Figure [3](#F3){ref-type="fig"}**). For proliferation studies, these T47D-SOAT cells were incubated under increasing concentrations of E~1~S at 10^-12^ to 10^-4^M. As previously described ([@B40]), proliferation of T47D cells can be stimulated not only by E~2~, but also by E~1~S at higher concentrations. In the present study, we obtained a sigmoidal dose-response curve with an effective concentration (EC~50~) of 21.7 nM for the T47D-control cells, which is very close to previous data, being 17.1 nM ([@B40]). Interestingly, proliferation of the SOAT-expressing T47D-SOAT cells was stimulated already at much lower E~1~S concentrations and the dose-response curve revealed an EC~50~ of 2.2 nM, meaning a 10-fold increased sensitivity to E~1~S exposure. At physiological E~1~S concentrations, being in the order 10^-8^ to 10^-9^ M ([@B44]), the differences between the proliferations of T47D-SOAT vs. T47D-control cells were most pronounced (**Figure [4](#F4){ref-type="fig"}**). To ensure that this increased proliferation is indeed induced by SOAT-mediated import of E~1~S, the cells were co-incubated with E~1~S and the SOAT inhibitor 4-SMP ([@B18]). In these experiments, E~1~S was added at 10 nM to stimulate cell proliferation, representing a concentration at which T47D-SOAT cells showed significant sodium-dependent transport activity for \[^3^H\]E~1~S. Interestingly, 4-SMP completely blocked the E~1~S-mediated proliferation of T47D-SOAT cells and likewise that of T47D-control cells. To verify that 4-SMP itself does not cause inhibition of proliferation by any other effect than by inhibiting the E~1~S uptake, 4-SMP was additionally co-incubated with E~2~. In these experiments, the E~2~-stimulated proliferation of the T47D-SOAT cells was not affected by 4-SMP, indicating that 4-SMP had no effect on the direct estrogenic effect of E~2~, but only on the transport of E~1~S. The inhibiting effect of 4-SMP on the T47D-control cells could mean that here, residue E~1~S transport activity is inhibited even if SOAT is expressed at very low levels in the T47D-control cells. Another explanation would be that 4-SMP inhibits other E~1~S uptake transporters, such as OATP1A2, OATP2B1, OATP3A1, and OATP4A1, which have been detected previously in T47D cells ([@B47]; [@B40]; [@B36]). At least in the case of OAT3, 4-SMP has been described as inhibitor ([@B4]), indicating that 4-SMP is not selective for SOAT. However, if 4-SMP does interfere with the E~1~S transport via one of the mentioned OATPs must be elucidated.

Conclusion
==========

The present study demonstrates expression of SOAT in breast cancer tissue with ductal localization. SOAT inhibition can block the E~1~S-stimulated proliferation of T47D breast cancer cells and, therefore, in addition to the carriers of the OATP carrier family, can be regarded as a novel potential drug target for anti-proliferative breast cancer therapy. Very recently, novel inhibitors of SOAT were identified by pharmacophore modeling ([@B20]). After optimization, these compounds are interesting candidates for further breast cancer proliferation studies *in vitro* and *in vivo*. These studies should also include comparative transport inhibition of SOAT and carriers of the OATP and OAT families in order to find at best an inhibitor for E~1~S transport covering all uptake carriers in breast cancer cells.
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4-SMP

:   4-sulfooxymethylpyrene

DCC

:   dextran-coated charcoal

DHEAS

:   dehydroepiandrosterone sulfate

DMEM

:   Dulbecco's Modified Eagle's Medium

DMSO

:   dimethyl sulfoxide

E~1~

:   estrone

E~2~

:   estradiol

E~1~S

:   estrone-3-sulfate

ER

:   estrogen receptor

FCS

:   fetal calf serum

HER2

:   human epidermal growth factor receptor 2

IHC

:   immunohistochemistry

LC-MS-MS

:   liquid chromatography-tandem mass spectrometry

OAT

:   organic anion transporter

OATP

:   organic anion transporting polypeptide

PBS

:   phosphate buffered saline

PR

:   progesterone receptor

SOAT

:   sodium-dependent organic anion transporter

STS

:   steroid sulfatase

TN

:   triple negative
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